Core B: Clinical Core

核心 B：临床核心

• 批准号: 9761403
• 负责人: Jesse Benjamin Mez
• 金额: $ 69.91万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-15 至 2021-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9761403
• 关键词: African American; Agreement; Alzheimer' s Disease; Area; Autopsy; Biological Markers; Blood; Blood Vessels; Boston; Brain; Cells; Cessation of life; Clinical; Clinical Research; Clinical Trials; Cognitive; Communities; Consensus; Consent; DNA; Data; Data Coordinating Center; Data Set; Databases; Dementia; Development; Diagnosis; Diagnostic; Factor Analysis; Foundations; Funding; Genetic; Genetic Diseases; Genotype; Grant; Industry; International; Life; MRI Scans; Magnetic Resonance Imaging; Manufactured football; Methods; Neuropsychological Tests; Participant; Pathologic; Patient Recruitments; Pilot Projects; Prevention; Registries; Research; Research Personnel; Risk Factors; Sampling; Scanning; Source; Specimen; Time; United States National Institutes of Health; Universities; Work; aging brain; biomarker development; brain tissue; chronic traumatic encephalopathy; cognitive neuroscience; cohort; cooperative study; data management; data quality; data registry; data sharing; design; diagnosis quality; genomic biomarker; head impact; in vivo; mild cognitive impairment; multidisciplinary; neuroimaging; neuropathology; prognostic; programs; recruit; repository; research study; sample collection; statistics; symposium

The BU ADC Clinical Core (CC) conducts and enhances cutting-edge Alzheimer’s disease (AD) research. CC registry data and subject participation support local and national clinical research studies. We have successfully maintained approximately 20% African American representation in the registry. The CC obtains research-quality MRI scans on registry participants and CC investigators are actively engaged in, and make major contributions to national and international AD research endeavors, including genetics and genomics, biomarker development, cognitive and functional assessment, and cognitive neuroscience. CC investigators have also made significant contributions to the clinical description, diagnosis, and risk factor analysis of chronic traumatic encephalopathy (CTE). We have fully integrated the examination of CTE, with an emphasis on the comparison of CTE and AD, and have included a cohort of former National Football League (NFL) players in the CC registry. We also have integrated CC activities and methods with those of several funded studies of CTE affiliated with the CC. During the next funding cycle, the CC will have the following specific aims: Aim 1: To evaluate and longitudinally examine a registry of approximately 425 participants, comprised of: 50 cognitively normal controls without subjective cognitive complaints (SCC); 125 controls with SCC; 100 subjects with mild cognitive impairment; 75 subjects with mild-moderate AD dementia; and 75 former NFL players with extensive repetitive head impact exposure. Aim 2: To provide data and a source for well-characterized participants for local and national research studies on brain aging, AD spectrum, and CTE research. Research-quality diagnoses will be made on all participants through multidisciplinary diagnostic consensus conferences. High quality data will be collected and submitted to the National Alzheimer’s Coordinating Center (NACC) for data sharing with qualified investigators. The Registry was designed to meet the recruitment needs of the local and national AD research community. Aim 3: To obtain brain donation consents for a minimum of 75% of registry participants and to work with the Neuropathology Core (NPC) to successfully obtain brain tissue from a minimum of 90% of consented participants upon death. The CC and the NPC will examine clinicopathological agreements, with a special emphasis on the comparison of AD and CTE. Aim 4. To collect blood and CSF products from registry participants. The CC will work closely with the NPC to integrate the collection of specimens with the analysis, banking, and distribution of specimens. We will extract DNA and genotype APOE and provide samples to qualified AD and CTE researchers, the National Cell Repository for Alzheimer’s Disease and the Alzheimer’s Disease Genetics Consortium. Aim 5: To conduct research-quality MRI scans on a minimum of 85% of the registry to support AD- and CTE-related research. We will upload MRI data to NACC. The Neuroimaging section of the CC will conduct post-processing of scans and will make the data available to CC investigators and to others in the AD and CTE research communities.

BU ADC 临床核心 (CC) 开展并加强前沿的阿尔茨海默病 (AD) 研究。 CC 注册数据和受试者参与支持地方和国家临床研究。 CC 成功地在登记册中维持了大约 20% 的非裔美国人代表。 对注册参与者和 CC 研究人员积极参与的研究质量 MRI 扫描，并做出 对国家和国际AD研究工作的重大贡献，包括遗传学和基因组学， 生物标志物开发、认知和功能评估以及认知神经科学研究人员。 还对慢性病的临床描述、诊断和危险因素分析做出了重大贡献 我们已经完全整合了 CTE 的检查，重点是创伤性脑病 (CTE)。 CTE 和 AD 的比较，并且将一组前国家橄榄球联盟 (NFL) 球员纳入其中 我们还将 CC 活动和方法与多项受资助的 CTE 研究的活动和方法相结合。 隶属于 CC 在下一个资助周期中，CC 将实现以下具体目标： 目标 1：评估和纵向检查大约 425 名参与者的登记，包括 其中：50 名认知正常的对照组，无主观认知不适 (SCC)；125 名对照组有 SCC； 患有轻度认知障碍的受试者；75 名患有轻度至中度 AD 痴呆的受试者和 75 名前 NFL 球员 目标 2：提供充分表征的数据和来源。 当地和国家脑老化、AD 谱和 CTE 研究的参与者。 将通过多学科诊断共识对所有参与者进行研究质量的诊断 高质量的数据将被收集并提交给国家阿尔茨海默病协调中心。 (NACC) 与合格的调查人员共享数据，该登记处旨在满足招募需求。 目标 3：获得最低限度的大脑捐赠同意。 75% 的注册参与者并与神经病理学核心 (NPC) 合作成功获得 CC 和 NPC 将采集至少 90% 同意的参与者死亡后的脑组织。 检查临床病理学一致性，特别强调 AD 和 CTE 的比较 目标 4。 CC 将与 NPC 密切合作，以整合登记参与者的血液和脑脊液产品。 样本的收集以及样本的分析、储存和分发，我们将提取 DNA 并进行分析。 对 APOE 进行基因分型，并将样本提供给合格的 AD 和 CTE 研究人员、国家细胞存储库 阿尔茨海默病和阿尔茨海默病遗传学联盟目标 5：开展高质量的研究。 至少 85% 的登记处进行 MRI 扫描，以支持 AD 和 CTE 相关研究。 CC 的神经影像部分将进行 MRI 数据的扫描后处理，并进行扫描。 CC 研究人员以及 AD 和 CTE 研究界的其他人可以获得的数据。